Ironwood Pharmaceuticals (NASDAQ: IRON) plans 33,000-share sale via options exercise
Filing Impact
Filing Sentiment
Form Type
144
Rhea-AI Filing Summary
Ironwood Pharmaceuticals filed to sell common stock through Morgan Stanley Smith Barney LLC. The filing covers 33,000 shares of common stock with an aggregate market value of $2,527,470.00, expected to be sold on July 13, 2026 on NASDAQ. The shares are tied to an exercise of stock options for cash. The disclosure also notes prior Rule 10b5-1 sales for John Quisel of 34,000 shares of common stock on June 18, 2026 for proceeds of $2,387,296.40.
Positive
- None.
Negative
- None.
Key Figures
Shares planned for sale: 33,000 shares
Aggregate market value: $2,527,470.00
Prior 10b5-1 sale shares: 34,000 shares
+2 more
5 metrics
Shares planned for sale
33,000 shares
Common stock to be sold on or about July 13, 2026
Aggregate market value
$2,527,470.00
Market value of 33,000 common shares covered by the filing
Prior 10b5-1 sale shares
34,000 shares
Common shares sold on June 18, 2026 under 10b5-1 sales for John Quisel
Prior 10b5-1 sale value
$2,387,296.40
Proceeds from 34,000-share Rule 10b5-1 sale on June 18, 2026
Planned sale date
07/13/2026
Intended date for sale of 33,000 common shares
Key Terms
Form 144, Exercise of Stock Options, 10b5-1
3 terms
Form 144 regulatory
"144: Securities Information Common | Morgan Stanley Smith Barney LLC"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
Exercise of Stock Options financial
"Common | 07/13/2026 | Exercise of Stock Options | Issuer"
10b5-1 regulatory
"10b5-1 Sales for JOHN QUISEL 321 Arsenal Street"
A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.
FAQ
What stock sale is disclosed for IRON in this Form 144?
The filing covers a planned sale of 33,000 shares of Ironwood Pharmaceuticals common stock, with an aggregate market value of $2,527,470.00, expected to be sold on July 13, 2026 on NASDAQ.
Which broker is handling the planned IRON stock sale?
The planned sale of 33,000 shares of Ironwood Pharmaceuticals common stock is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, based at 1 New York Plaza, New York, NY 10004.
What recent Rule 10b5-1 sales are reported for IRON?
The filing notes Rule 10b5-1 sales for John Quisel of 34,000 shares of Ironwood Pharmaceuticals common stock on June 18, 2026, with total proceeds of $2,387,296.40 from those sales.